Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Nektar Therapeutics (NKTR): Are Hedge Funds Right About This Stock?

We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Nektar Therapeutics (NASDAQ:NKTR) based on that data.

Nektar Therapeutics (NASDAQ:NKTR) has experienced an increase in hedge fund sentiment in recent months. NKTR was in 27 hedge funds’ portfolios at the end of the third quarter of 2018. There were 24 hedge funds in our database with NKTR holdings at the end of the previous quarter. Our calculations also showed that NKTR isn’t among the 30 most popular stocks among hedge funds.

In today’s marketplace there are numerous formulas stock traders have at their disposal to appraise their holdings. A couple of the most useful formulas are hedge fund and insider trading sentiment. Our experts have shown that, historically, those who follow the best picks of the elite money managers can outpace their index-focused peers by a healthy amount (see the details here).


We’re going to review the latest hedge fund action regarding Nektar Therapeutics (NASDAQ:NKTR).

What does the smart money think about Nektar Therapeutics (NASDAQ:NKTR)?

At Q3’s end, a total of 27 of the hedge funds tracked by Insider Monkey were long this stock, a change of 13% from the previous quarter. Below, you can check out the change in hedge fund sentiment towards NKTR over the last 13 quarters. With the smart money’s sentiment swirling, there exists an “upper tier” of key hedge fund managers who were increasing their holdings significantly (or already accumulated large positions).


More specifically, Camber Capital Management was the largest shareholder of Nektar Therapeutics (NASDAQ:NKTR), with a stake worth $91.4 million reported as of the end of September. Trailing Camber Capital Management was Cormorant Asset Management, which amassed a stake valued at $83.5 million. Cormorant Asset Management, Bridger Management, and Millennium Management were also very fond of the stock, giving the stock large weights in their portfolios.

As aggregate interest increased, specific money managers have jumped into Nektar Therapeutics (NASDAQ:NKTR) headfirst. EcoR1 Capital, managed by Oleg Nodelman, established the most outsized call position in Nektar Therapeutics (NASDAQ:NKTR). EcoR1 Capital had $19.8 million invested in the company at the end of the quarter. Ori Hershkovitz’s Nexthera Capital also made a $7.8 million investment in the stock during the quarter. The other funds with brand new NKTR positions are Jeffrey Talpins’s Element Capital Management, Israel Englander’s Millennium Management, and George Zweig, Shane Haas and Ravi Chander’s Signition LP.

Let’s now take a look at hedge fund activity in other stocks – not necessarily in the same industry as Nektar Therapeutics (NASDAQ:NKTR) but similarly valued. We will take a look at Atmos Energy Corporation (NYSE:ATO), Tata Motors Limited (NYSE:TTM), Leidos Holdings Inc (NYSE:LDOS), and Packaging Corporation Of America (NYSE:PKG). All of these stocks’ market caps match NKTR’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
ATO 15 168216 -2
TTM 9 120349 -3
LDOS 27 472777 0
PKG 26 315125 0
Average 19.25 269117 -1.25

View table here if you experience formatting issues.

As you can see these stocks had an average of 19.25 hedge funds with bullish positions and the average amount invested in these stocks was $269 million. That figure was $418 million in NKTR’s case. Leidos Holdings Inc (NYSE:LDOS) is the most popular stock in this table. On the other hand Tata Motors Limited (NYSE:TTM) is the least popular one with only 9 bullish hedge fund positions. Nektar Therapeutics (NASDAQ:NKTR) is not the most popular stock in this group but hedge fund interest is still above average. This is a slightly positive signal but we’d rather spend our time researching stocks that hedge funds are piling on. In this regard LDOS might be a better candidate to consider a long position.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.